Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.72 |
| ▸ | LPL | P06858 | 4/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258005 | 0.94 | DGAT1 (0.64) | DGAT1LPLLIPGMMP2MMP13 | |
| SCHEMBL10281613 | 0.92 | DGAT1 (0.63) | DGAT1LPLLIPGMMP2MMP13 | |
| SCHEMBL17129607 | 0.86 | DGAT1 (0.56) | DGAT1LPLLIPGHIF1AMAOB | |
| SCHEMBL21234416 | 0.86 | DGAT1 (0.56) | DGAT1LPLLIPGHIF1AMAOB | |
| SCHEMBL2267580 | 0.86 | DGAT1 (0.56) | DGAT1LPLLIPGMAOBRAB9A | |
| SCHEMBL15981216 | 0.85 | DGAT1 (0.55) | DGAT1LPLLIPGHIF1ACA1 | |
| SCHEMBL257763 | 0.85 | DGAT1 (0.55) | DGAT1LPLLIPGMAOBMAOA | |
| SCHEMBL21568905 | 0.85 | LPL (0.59) | DGAT1LPLLIPGMAOBCA1 | |
| SCHEMBL15981217 | 0.85 | DGAT1 (0.55) | DGAT1LPLLIPGHIF1ACA1 | |
| SCHEMBL27345599 | 0.85 | DGAT1 (0.56) | DGAT1LPLLIPGMMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025244832-A1 | NOVEL AMINOGUANIDINE DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | KONG'S PHARMACEUTICAL CO. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| EP-4389749-A1 | SUBSTITUTED 3,7-DIHYDRO-1H-PURINE-2,6-DIONES AND USE THEREOF | invIOs GmbH (AT) | 2024-06-26 | — | — | EP | disclosed |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| EP-2427454-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2361251-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010010186-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| US-7329668-B2 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | DGAT1 3132/4885LPL 3028/4885LIPG 3200/4885 |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | DGAT1 2037/4885LPL 3869/4885LIPG 1634/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | DGAT1 3247/4885LPL 2814/4885LIPG 1673/4885 |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | PDE3A, PDE2A, PDE5A | DGAT1 2835/4885LPL 408/4885LIPG 183/4885 |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE1, WEE2 | DGAT1 1725/4885LPL 3691/4885LIPG 3280/4885 |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE2, WEE1 | DGAT1 1878/4885LPL 3112/4885LIPG 1966/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | DGAT1 2437/4885LPL 4151/4885LIPG 3269/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | DGAT1 2441/4885LPL 3263/4885LIPG 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.